Table 4.

Univariable (Kaplan-Meier) and multivariable (Cox proportional-hazards) analysis of patient-related factors for time to progression and overall survival time. Hazard Ratio and 95% Confidence interval is reported

	N. of patients	Overall Survival [Univariable]	P	[Multivariable]	P	TTP [Univariable]	P	[Multivariable]	P
Sex
Male	35	1.58 (0.95–2.63)	0.0634	–	–	1.67 (0.99–2.75)	0.0433	–	–
Female	30			–	–			–	–
Location
Rostral	34	0.71 (0.43–1.16)	0.1596	–	–	0.77 (0.47–1.26)	0.2921	–	–
Caudal	31			–	–			–	–
Metastasis
No (or lynph node only)	55	0.29 (0.09–0.88)	0.0001	–	–	0.34 (0.12–0.96)	0.0009	–	–
Yes	10			–	–			–	–
Bone Involvement
Yes	42	2.45 (1.50–4.00)	0.0004
No	23			(0.24–0.88)	0.0184	0.42 (0.26–0.68)	0.0005	(0.28–0.98)	0.043
Histology
Epithelioid vs. Fusocellular	16 / 16	0.59 (0.31–1.14)	0.1768	–	–	0.60 (0.32–1.14)	0.0534	–	–
Epithelioid vs Mixed.	16 / 17	0.54 (0.28–1.05)		–	–	0.49 (0.25–0.96)		–	–
Epithelioid vs. Anaplastic	16 / 9	0.46 (0.19–1.11)		–	–	0.35 (0.14–0.93)		–	–
Fusocellular vs. Mixed	16 / 17	0.92 (0.44–1.93)		–	–	0.82 (0.39–1.72)		–	–
Fusocellular vs. Anaplastic	16 / 9	0.77 (0.30–1.99)		–	–	0.59 (0.22–1.64)		–	–
Mixed vs. Anaplastic	17 / 9	0.84 (0.33–2.18)		–	–	0.73 (0.26–2.04)		–	–
Stage
I vs. II	10 / 18	1.86 (1.03–3.34)	<0.0001	Stage I: (0.13–0.74)	0.0083	0.53 (0.30–0.96)	0.0001	Stage I: (0.07 –0.47)	0.0005
I vs. III	10 / 26	3.28 (1.76–6.09)				0.28 (0.15–0.53)		Stage II: (0.24–0.82)	0.0094
I vs. IV	10 / 11	9.05 (2.58–31.75)				0.19 (0.07–0.51)
II vs. III	18 / 26	0.57 (0.30–1.06)				0.52 (0.27–0.99)
II vs. IV	18 / 11	0.21 (0.06–0.72)		Stage IV:(2.04–9.29)	0.0001	0.35 (0.13–0.96)
III vs IV	26 / 11	0.36 (0.10–1.29)				0.67 (0.24–1.90)